Liquidia Late Friday Announced US Patent Trial And Appeal Board Ruled In Favor In Inter Partes Review Proceeding Against United Therapeutics’ ‘901 Patent
Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 9,604,901 (‘901 patent)
FDA Completes On-site Pre-Approval Inspection Of Liquidia’s Morrisville, North Carolina Facility
Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection (PAI) of its Morrisville, North Carolina facility in connection with
US Patent Trial And Trademark Appeal Board Decides To Institute Inter Partes Review Of United Therapeutics’ Tyvaso Patent
Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) against U.S. Patent No. 10,716,793 (‘793 patent), owned by United
Liquidia Technologies Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $3.38M Beat $1.72M Estimate
Liquidia Technologies (NASDAQ:LQDA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 73.47 percent increase over losses of $(0.49) per share
Liquidia: Q2 Earnings Insights
Shares of Liquidia (NASDAQ:LQDA) fell 0.8% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 73.47% year over year to ($0.13), which beat the estimate of ($0.15).
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.